当前位置:首页 - 行情中心 - 海辰药业(300584) - 财务分析 - 现金流量表

海辰药业

(300584)

  

流通市值:23.14亿  总市值:33.80亿
流通股本:8213.15万   总股本:1.20亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金304,593,423.01154,373,379.56644,155,755.46454,087,572.94
  收到的税费返还13,179,604.2213,179,604.2217,883,14417,883,144
  收到其他与经营活动有关的现金1,272,977.96632,792.232,008,971.415,756,342.6
  经营活动现金流入小计319,046,005.19168,185,776.01664,047,870.87477,727,059.54
  购买商品、接受劳务支付的现金36,867,022.0617,935,666.3558,711,474.6729,274,321.73
  支付给职工以及为职工支付的现金46,769,480.324,537,637.7973,950,268.1256,591,262.3
  支付的各项税费67,929,681.8236,450,300.89100,128,343.0870,015,508.74
  支付其他与经营活动有关的现金168,357,886.7878,647,649.92353,168,652.13263,359,297.98
  经营活动现金流出小计319,924,070.96157,571,254.95585,958,738419,240,390.75
  经营活动产生的现金流量净额-878,065.7710,614,521.0678,089,132.8758,486,668.79
二、投资活动产生的现金流量:
  收回投资收到的现金--1,000,344.951,000,344.95
  处置固定资产、无形资产和其他长期资产收回的现金净额37,169.3937,134.8829,500,00059,076,534.11
  投资活动现金流入小计37,169.3937,134.8830,500,344.9560,076,879.06
  购建固定资产、无形资产和其他长期资产支付的现金17,253,988.7713,113,744.1162,639,934.1157,109,231.52
  投资支付的现金--9,100,0009,100,000
  投资活动现金流出小计17,253,988.7713,113,744.1171,739,934.1166,209,231.52
  投资活动产生的现金流量净额-17,216,819.38-13,076,609.23-41,239,589.16-6,132,352.46
三、筹资活动产生的现金流量:
  吸收投资收到的现金--33,500,00015,000,000
  其中:子公司吸收少数股东投资收到的现金--33,500,00015,000,000
  取得借款收到的现金105,000,00048,000,000234,300,000169,500,000
  收到其他与筹资活动有关的现金9,919,111.119,919,111.1118,600,00018,600,000
  筹资活动现金流入小计114,919,111.1157,919,111.11286,400,000203,100,000
  偿还债务支付的现金105,290,00037,890,000222,100,000161,300,000
  分配股利、利润或偿付利息支付的现金15,452,154.691,741,315.0919,504,656.9617,699,582.34
  支付其他与筹资活动有关的现金19,376,134.7810,776,134.7861,229,869.0646,089,174.15
  筹资活动现金流出小计140,118,289.4750,407,449.87302,834,526.02225,088,756.49
  筹资活动产生的现金流量净额-25,199,178.367,511,661.24-16,434,526.02-21,988,756.49
四、汇率变动对现金及现金等价物的影响-12,540.04-8,046.2317,092.5919,877.48
五、现金及现金等价物净增加额-43,306,603.555,041,526.8420,432,110.2830,385,437.32
  加:期初现金及现金等价物余额66,190,828.1166,190,828.1145,758,717.8345,758,717.83
  期末现金及现金等价物余额22,884,224.5671,232,354.9566,190,828.1176,144,155.15
补充资料:
  净利润32,892,970.11-40,732,040.52-
  资产减值准备8,428,855.68-10,921,264.4-
  固定资产和投资性房地产折旧24,344,493.44-35,775,392.74-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧24,344,493.44-35,775,392.74-
  无形资产摊销11,196,891.46-28,189,738.5-
  长期待摊费用摊销40,474.92-53,966.56-
  处置固定资产、无形资产和其他长期资产的损失1,067.99--482,279.37-
  固定资产报废损失265,521.83-694,556.94-
  公允价值变动损失--22,693,335.71-
  财务费用2,638,959.32-6,586,067.09-
  投资损失1,629,074.36-3,592,696.24-
  递延所得税-1,173,192.99--14,395,984.3-
  其中:递延所得税资产减少-1,010,453.69--5,494,658.59-
    递延所得税负债增加-162,739.3--8,901,325.71-
  存货的减少-19,961,518.1-2,258,633.79-
  经营性应收项目的减少-31,251,263.67--70,774,028.9-
  经营性应付项目的增加-30,271,136.58-11,675,838.85-
  不涉及现金收支的投资和筹资活动金额其他项目--2,044,418.59-
  现金的期末余额22,884,224.56-66,190,828.11-
  减:现金的期初余额66,190,828.11-45,758,717.83-
  现金及现金等价物的净增加额-43,306,603.55-20,432,110.28-
公告日期2026-08-252026-04-252026-04-252025-10-23
审计意见(境内)标准无保留意见
TOP↑